Mr. Cao Xu is currently a partner at CDH Investments and previously held positions as a lead engineer at Bayer Pharmaceuticals (Asia) and as a VP at CCB International Asset Management (Beijing). Mr. Cao specializes in medical investment and has over ten years of experience in the field. His investment portfolio includes companies such as Ascentage Pharma, Kintor Pharma, CF Pharmtech, Adagene, Thousand Oaks Biopharm, Immunocore, TJR Bioscience, IASO BioTherapeutics, and Cloudbreak Therapeutics. Mr. Cao holds a Bachelor's and Master's degree in Bioengineering from Zhejiang University.
Partner, CDH Investments
Michael Lai is the General Manager for AstraZeneca China since Jan 2019, overseeing the largest pharmaceutical company in China with over $5Bn in sales and a team of approximately 20,000. Prior to this role, he managed progressively increasing business as unit head in China at AstraZeneca and Sanofi from 2011-2018, and worked as a Project Leader at the Boston Consulting Group from 2007-2010, where he focused on healthcare management and strategy engagements across the spectrum of pharmaceuticals, medical devices, diagnostics, and consumer healthcare primarily in China and Asia. Dr. Lai holds a B.A. in Biological Sciences from Harvard University and an M.D. from the University of California, San Francisco, and is a board-certified physician in the United States.
Tiantian (Stanley) Li is the founder and chairman of DXY (丁香园). DXY is a leading digital healthcare technology company in China, which has covered more than 70% of Chinese doctors nationwide. DXY provided the first COVID-19 Map in the world in January 2020, and it became the working basis of the Johns Hopkins Coronavirus Resource Center.
Through professional and evidence-based knowledge sharing, rich and comprehensive product offerings, and high-quality digital healthcare services, DXY connects doctors, researchers, patients, consumers, hospitals, and the pharma industry. Since its establishment 23 years ago, it has served more than 100 million users. "More health, Better Life" is the company's vision.
Tiantian Li (Stanley) holds a bachelor's degree in clinical medicine and a master's degree in tumor immunology from Harbin Medical University. Currently, he is an expert on the Innovation Challenge of the Western Pacific Region of the World Health Organization (WHO), the vice president of the Internet Medical Health Branch of China Non-Public Medical Institutions Association, and the vice president of the Medical and Health Industry Branch of China Information Association. In addition, he is visiting professor at Harbin Medical University and the School of Management Shanghai Jiao Tong University. He is also the vice president of the Zhejiang Health Service Promotion Association and Heilongjiang Health Industry Association.
Founder and Chairman, DXY
Dr. Bozhi Tian earned his Ph.D. in Physical Chemistry from Harvard University. He then undertook postdoctoral studies at the Massachusetts Institute of Technology (MIT) and Harvard Medical School, specializing regenerative medicine and tissue engineering. His current research is centered around the development of novel materials for bioelectronics, with a particular emphasis on semiconductor-enabled approaches to unravel the complexities of subcellular biophysics. In addition, Dr. Tian is actively investigating the dynamics at soft-hard interfaces, a subject with potential implications in various scientific and technological domains such as minimally invasive medical implants. Recognized for his significant contributions to the scientific community, Dr. Tian has been the recipient of numerous awards and honors. Among these are the Raymond and Beverly Sackler International Prize in Chemistry, Presidential Early Career Awards for Scientists and Engineers (PECASE) and 35 Innovators Under 35 (TR35) by the MIT Technology Review. By bridging the gap between materials science, biology, and engineering, he has positioned himself as an explorer in the rapidly evolving field of bioelectronics.
Professor at the University of Chicago
In the post-pandemic era, the healthcare industry is exploring novel mean of effecting change through the realms of artificial intelligence and biotechnology. With the growth of the patient population served by e-health in China, the nation is seeking to close the gap left by industry pioneers across the world. Moreover, policies affecting volume-based procurement are squeezing the profit margins of healthtech firms, aggravating competition in the industry. Such a context begs the question: what do the panelists anticipate for future development in the industry? What path will firms in the Chinese healthtech space choose? This year's panel seeks to tackle such questions and their relation to the Chinese-American healthcare space.